Review ArticleSystematic Review
Open Access

Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients

Peng Chen, Ye-Qi Sun, Guo-Ping Yang, Rong Li, Jie Pan and Yu-Sheng Zhou
Saudi Medical Journal April 2016, 37 (4) 361-368; DOI: https://doi.org/10.15537/smj.2016.4.14036

References

  1. ↵
    1. Ansell J,
    2. Hirsh J,
    3. Poller L,
    4. Bussey H,
    5. Jacobson A,
    6. Hylek E
    (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl 3):S204–S233.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Hart RG,
    2. Pearce LA,
    3. Aguilar MI
    (2007) Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–67.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348:633–638.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Burns M
    (1999) Management of narrow therapeutic index drugs. J Thromb Thrombolysis 7:137–143.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Wadelius M,
    2. Pirmohamed M
    (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99–111.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Ansell J,
    2. Hirsh J,
    3. Hylek E,
    4. Jacobson A,
    5. Crowther M,
    6. Palareti G,
    7. et al.
    (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl 6):S160–S198.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Hylek EM,
    2. Evans-Molina C,
    3. Shea C,
    4. Henault LE,
    5. Regan S
    (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689–2696.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kirkwood TB
    (1983) Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 49:238–244.
    OpenUrlPubMedWeb of Science
  9. ↵
    1. Jorgensen AL,
    2. FitzGerald RJ,
    3. Oyee J,
    4. Pirmohamed M,
    5. Williamson PR
    (2012) Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 7:e44064.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Teichert M,
    2. van Schaik RH,
    3. Hofman A,
    4. Uitterlinden AG,
    5. de Smet PA,
    6. Stricker BH,
    7. et al.
    (2009) Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther 85:379–386.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. International Warfarin Pharmacogenetics Consortium,
    2. Klein TE,
    3. Altman RB,
    4. Eriksson N,
    5. Gage BF,
    6. Kimmel SE,
    7. et al.
    (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753–764.
    OpenUrlCrossRefPubMedWeb of Science
    1. Avery PJ,
    2. Jorgensen A,
    3. Hamberg AK,
    4. Wadelius M,
    5. Pirmohamed M,
    6. Kamali F,
    7. et al.
    (2011) A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther 90:701–706.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Lenzini P,
    2. Wadelius M,
    3. Kimmel S,
    4. Anderson JL,
    5. Jorgensen AL,
    6. Pirmohamed M,
    7. et al.
    (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87:572–578.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Verhoef T,
    2. Ragia G,
    3. de Boer A,
    4. Barallon R,
    5. Kolovou G,
    6. Kolovou V,
    7. et al.
    (2013) A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 369:2304–2312.
    OpenUrlCrossRefPubMedWeb of Science
    1. Pirmohamed M,
    2. Burnside G,
    3. Eriksson N,
    4. Jorgensen AL,
    5. Toh CH,
    6. Nicholson T,
    7. et al.
    (2013) A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369:2294–2303.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kimmel SE,
    2. French B,
    3. Kasner SE,
    4. Johnson JA,
    5. Anderson JL,
    6. Gage BF,
    7. et al.
    (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369:2283–2293.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Baranova EV,
    2. Asselbergs FW,
    3. de Boer A,
    4. Maitland-van der Zee AH
    (2014) The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation? Curr Mol Med 14:841–848.
    OpenUrl
  18. ↵
    1. Caldwell MD,
    2. Awad T,
    3. Johnson JA,
    4. Gage BF,
    5. Falkowski M,
    6. Gardina P,
    7. et al.
    (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106–4112.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. McDonald MG,
    2. Rieder MJ,
    3. Nakano M,
    4. Hsia CK,
    5. Rettie AE
    (2009) CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75:1337–1346.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Danese E,
    2. Montagnana M,
    3. Johnson JA,
    4. Rettie AE,
    5. Zambon CF,
    6. Lubitz SA,
    7. et al.
    (2012) Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther 92:746–756.
    OpenUrlPubMed
  21. ↵
    1. Ramirez AH,
    2. Shi Y,
    3. Schildcrout JS,
    4. Delaney JT,
    5. Xu H,
    6. Oetjens MT,
    7. et al.
    (2012) Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 13:407–418.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Krishna Kumar D,
    2. Shewade DG,
    3. Loriot MA,
    4. Beaune P,
    5. Sai Chandran BV,
    6. Balachander J,
    7. et al.
    (2015) An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. Eur J Clin Pharmacol 71:173–181.
    OpenUrl
  23. ↵
    1. Scott SA,
    2. Khasawneh R,
    3. Peter I,
    4. Kornreich R,
    5. Desnick RJ
    (2010) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11:781–791.
    OpenUrlCrossRefPubMedWeb of Science
    1. Cavallari LH,
    2. Langaee TY,
    3. Momary KM,
    4. Shapiro NL,
    5. Nutescu EA,
    6. Coty WA,
    7. et al.
    (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87:459–464.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Rusdiana T,
    2. Araki T,
    3. Nakamura T,
    4. Subarnas A,
    5. Yamamoto K
    (2013) Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol 69:395–405.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Hylek EM,
    2. Skates SJ,
    3. Sheehan MA,
    4. Singer DE
    (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Hylek EM,
    2. Go AS,
    3. Chang Y,
    4. Jensvold NG,
    5. Henault LE,
    6. Selby JV,
    7. et al.
    (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019–1026.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Budnitz DS,
    2. Lovegrove MC,
    3. Shehab N,
    4. Richards CL
    (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002–2012.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Hylek EM,
    2. Singer DE
    (1994) Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120:897–902.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Stang A
    (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Higgins JP,
    2. Thompson SG
    (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Bejarano-Achache I,
    2. Levy L,
    3. Mlynarsky L,
    4. Bialer M,
    5. Muszkat M,
    6. Caraco Y
    (2012) Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clin Ther 34:811–823.
    OpenUrlPubMed
  33. ↵
    1. Cerezo-Manchado JJ,
    2. Roldan V,
    3. Rosafalco M,
    4. Anton AI,
    5. Arroyo AB,
    6. Garcia-Barbera N,
    7. et al.
    (2014) Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics 15:987–996.
    OpenUrl
  34. ↵
    1. Kawai VK,
    2. Cunningham A,
    3. Vear SI,
    4. Van Driest SL,
    5. Oginni A,
    6. Xu H,
    7. et al.
    (2014) Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 15:1973–1983.
    OpenUrlPubMed
  35. ↵
    1. Ma C,
    2. Zhang Y,
    3. Xu Q,
    4. Yang J,
    5. Zhang Y,
    6. Gao L,
    7. et al.
    (2012) Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Int J Hematol 96:719–728.
    OpenUrl
  36. ↵
    1. Roth JA,
    2. Boudreau D,
    3. Fujii MM,
    4. Farin FM,
    5. Rettie AE,
    6. Thummel KE,
    7. et al.
    (2014) Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther 95:636–643.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Shaw K,
    2. Amstutz U,
    3. Hildebrand C,
    4. Rassekh SR,
    5. Hosking M,
    6. Neville K,
    7. et al.
    (2014) VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer 61:1055–1062.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Jimenez-Varo E,
    2. Canadas-Garre M,
    3. Henriques CI,
    4. Pinheiro AM,
    5. Gutierrez-Pimentel MJ,
    6. Calleja-Hernandez MA
    (2014) Pharmacogenetics role in the safety of acenocoumarol therapy. Thromb Haemost 112:522–536.
    OpenUrl
  39. ↵
    1. Zhang JE,
    2. Jorgensen AL,
    3. Alfirevic A,
    4. Williamson PR,
    5. Toh CH,
    6. Park BK,
    7. et al.
    (2009) Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 19:781–789.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Beinema M,
    2. Brouwers JRBJ,
    3. Schalekamp T,
    4. Wilffert B
    (2008) Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 100:1052–1057.
    OpenUrlPubMedWeb of Science
  41. ↵
    1. Connolly SJ,
    2. Ezekowitz MD,
    3. Yusuf S,
    4. Eikelboom J,
    5. Oldgren J,
    6. Parekh A,
    7. et al.
    (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151.
    OpenUrlCrossRefPubMedWeb of Science
    1. Granger CB,
    2. Alexander JH,
    3. McMurray JJ,
    4. Lopes RD,
    5. Hylek EM,
    6. Hanna M,
    7. et al.
    (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992.
    OpenUrlCrossRefPubMedWeb of Science
    1. Patel MR,
    2. Mahaffey KW,
    3. Garg J,
    4. Pan G,
    5. Singer DE,
    6. Hacke W,
    7. et al.
    (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. Giugliano RP,
    2. Ruff CT,
    3. Braunwald E,
    4. Murphy SA,
    5. Wiviott SD,
    6. Halperin JL,
    7. et al.
    (2013) Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 369:2093–2104.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Reddy VY,
    2. Sievert H,
    3. Halperin J,
    4. Doshi SK,
    5. Buchbinder M,
    6. Neuzil P,
    7. et al.
    (2014) Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312:1988–1998.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Arepally GM,
    2. Ortel TL
    (2015) Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annu Rev Med 66:241–253.
    OpenUrlCrossRefPubMed
    1. Mega JL
    (2011) A new era for anticoagulation in atrial fibrillation. N Engl J Med 365:1052–1054.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Baker WL,
    2. Chamberlin KW
    (2014) New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? Clin Pharmacol Ther 96:17–19.
    OpenUrl
  49. ↵
    1. Yang J,
    2. Chen Y,
    3. Li X,
    4. Wei X,
    5. Chen X,
    6. Zhang L,
    7. et al.
    (2013) Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 168:4234–4243.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Nahar R,
    2. Saxena R,
    3. Deb R,
    4. Parakh R,
    5. Shad S,
    6. Sethi PK,
    7. et al.
    (2014) CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. Pharmacol Rep 66:243–249.
    OpenUrl
    1. Tatarunas V,
    2. Lesauskaite V,
    3. Veikutiene A,
    4. Grybauskas P,
    5. Jakuska P,
    6. Jankauskiene L,
    7. et al.
    (2014) The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery. J Thromb Thrombolysis 37:177–185.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Pautas E,
    2. Moreau C,
    3. Gouin-Thibault I,
    4. Golmard JL,
    5. Mahe I,
    6. Legendre C,
    7. et al.
    (2010) Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 87:57–64.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    1. Schwarz UI,
    2. Ritchie MD,
    3. Bradford Y,
    4. Li C,
    5. Dudek SM,
    6. Frye-Anderson A,
    7. et al.
    (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999–1008.
    OpenUrlCrossRefPubMedWeb of Science
  54. ↵
    1. Skov J,
    2. Bladbjerg EM,
    3. Leppin A,
    4. Jespersen J
    (2013) The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thromb Res 131:125–129.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section